Verona Pharma (VRNA) Financials

$74.73 +2.15 (+2.96%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for Verona Pharma

This table shows Verona Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-173	-54	-69	-56	-65	-41	-25	-28	-6.19	-11
Consolidated Net Income / (Loss)	-173	-54	-69	-56	-65	-41	-25	-28	-6.19	-11
Net Income / (Loss) Continuing Operations	-173	-54	-69	-56	-65	-41	-25	-28	-6.19	-11
Total Pre-Tax Income	-163	-54	-68	-56	-65	-40	-31	-34	-7.37	-13
Total Operating Income	-155	-68	-76	-73	-74	-52	-33	-40	-8.66	-13
Total Gross Profit	42	0.00	0.46	40	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	42	0.00	0.46	40	0.00	0.00	0.00	0.00	0.00	0.00
Operating Revenue	42	0.00	0.46	40	0.00	-	-	-	-	-
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	197	68	76	113	74	52	33	40	8.66	13
Selling, General & Admin Expense	152	50	27	34	30	9.99	8.02	8.16	3.08	2.51
Research & Development Expense	45	17	49	79	45	42	25	32	5.58	11
Total Other Income / (Expense), net	-8.50	14	7.30	18	9.28	12	1.86	6.15	1.29	-0.04
Interest Expense	27	2.06	1.34	0.34	0.04	0.00	1.69	3.33	0.98	0.11
Interest & Investment Income	15	13	2.82	0.01	0.12	0.96	3.55	9.48	2.27	0.07
Other Income / (Expense), net	3.43	2.97	5.82	18	9.19	11	-	-	-	-
Income Tax Expense	10	0.47	0.25	-0.02	0.15	0.07	-5.39	-6.36	-1.18	-2.22
Basic Earnings per Share	($0.27)	($0.09)	($0.13)	($0.12)	($0.25)	($0.39)	($18.90)	($23.40)	($0.15)	($37.10)
Weighted Average Basic Shares Outstanding	652.31M	634.14M	529.07M	482.94M	463.48M	105.33M	105.33M	105.02M	-	-
Diluted Earnings per Share	($0.27)	($0.09)	($0.13)	($0.12)	($0.25)	($0.39)	($18.90)	($23.40)	($0.15)	($37.10)
Weighted Average Diluted Shares Outstanding	652.31M	634.14M	529.07M	482.94M	463.48M	105.33M	105.33M	105.02M	-	-
Weighted Average Basic & Diluted Shares Outstanding	679.83M	646.52M	631.90M	482.94M	463.48M	105.33M	105.33M	105.02M	-	-

This table shows Verona Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-16	-34	-43	-71	-26	-14	-15	-8.81	-17	-10	-16
Consolidated Net Income / (Loss)	-16	-34	-43	-71	-26	-14	-15	-8.81	-17	-10	-16
Net Income / (Loss) Continuing Operations	-16	-34	-43	-71	-26	-14	-15	-8.81	-17	-10	-16
Total Pre-Tax Income	-17	-26	-43	-70	-25	-14	-15	-8.50	-17	-10	-16
Total Operating Income	-10	-18	-41	-68	-27	-19	-16	-9.97	-22	-15	-15
Total Gross Profit	76	37	5.62	0.00	0.00	-	0.00	0.00	0.00	0.46	0.00
Total Revenue	76	37	5.62	0.00	0.00	-	0.00	0.00	0.00	0.46	0.00
Operating Revenue	76	-	-	-	-	-	-	-	-	-	-
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	87	55	46	68	27	19	16	9.97	22	16	15
Selling, General & Admin Expense	73	47	36	49	20	15	13	12	9.59	8.67	5.29
Research & Development Expense	14	7.87	11	19	6.76	4.12	2.96	-2.47	13	6.84	9.84
Total Other Income / (Expense), net	-6.24	-7.22	-2.05	-1.40	2.16	4.91	1.67	1.47	5.63	4.63	-0.46
Interest Expense	11	10	9.88	5.41	1.59	0.62	0.40	0.74	0.29	1.05	0.12
Interest & Investment Income	3.89	3.99	4.75	3.14	3.38	3.29	3.39	3.40	2.68	1.86	0.78
Other Income / (Expense), net	0.47	-0.89	3.09	0.87	0.37	2.24	-1.32	-1.19	3.25	3.81	-1.12
Income Tax Expense	-0.24	8.27	0.25	1.01	0.75	-0.05	0.04	0.31	0.17	0.03	0.06
Basic Earnings per Share	($0.02)	($0.05)	($0.07)	($0.11)	($0.04)	($0.03)	($0.02)	($0.01)	($0.03)	($0.01)	($0.03)
Weighted Average Basic Shares Outstanding	679.41M	652.31M	651.94M	648.22M	645.70M	634.14M	638.24M	634.47M	621.45M	529.07M	544.13M
Diluted Earnings per Share	($0.02)	($0.05)	($0.07)	($0.11)	($0.04)	($0.03)	($0.02)	($0.01)	($0.03)	($0.01)	($0.03)
Weighted Average Diluted Shares Outstanding	679.41M	652.31M	651.94M	648.22M	645.70M	634.14M	638.24M	634.47M	621.45M	529.07M	544.13M
Weighted Average Basic & Diluted Shares Outstanding	681.06M	679.83M	654.65M	649.88M	648.65M	646.52M	639.52M	635.88M	635.67M	631.90M	604.98M

This table details how cash moves in and out of Verona Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	128	44	79	-40	158	5.19	-16	-9.35	44	-9.50
Net Cash From Operating Activities	-122	-50	-60	-33	-45	-43	23	28	-6.89	9.37
Net Cash From Continuing Operating Activities	-122	-50	-60	-33	-45	-43	-23	-28	-6.89	-9.37
Net Income / (Loss) Continuing Operations	-173	-54	-69	-56	-65	-41	-31	-34	-7.37	-13
Consolidated Net Income / (Loss)	-173	-54	-69	-56	-65	-41	-31	-34	-7.37	-13
Depreciation Expense	1.06	0.68	0.64	0.63	0.62	0.51	0.01	0.01	0.01	0.01
Amortization Expense	1.42	0.22	0.19	0.24	0.02	0.00	0.11	0.16	0.06	0.06
Non-Cash Adjustments To Reconcile Net Income	56	17	19	8.00	22	1.45	1.02	-2.42	-2.81	1.95
Changes in Operating Assets and Liabilities, net	-6.84	-14	-11	13	-2.11	-4.27	6.52	8.35	3.21	1.88
Net Cash From Investing Activities	-0.58	0.00	-0.03	-0.01	9.71	47	6.73	-67	-0.05	-0.14
Net Cash From Continuing Investing Activities	-0.58	0.00	-0.03	-0.01	9.71	47	6.73	-67	-0.05	-0.14
Purchase of Property, Plant & Equipment	-0.58	0.00	-0.03	-0.01	-0.08	-0.05	-0.34	-0.01	-0.02	-0.00
Net Cash From Financing Activities	251	93	141	-6.12	192	0.00	0.00	85	51	0.00
Net Cash From Continuing Financing Activities	251	93	141	-6.12	192	0.00	0.00	85	51	0.00
Repayment of Debt	-59	29	-6.10	0.00	-0.11	0.00	0.00	0.00	-	-
Repurchase of Common Equity	0.00	0.00	-9.53	0.00	-13	0.00	0.00	-	-0.78	-
Issuance of Debt	123	10.00	10	0.00	5.00	0.00	-	-	-	-
Issuance of Common Equity	97	57	150	0.73	200	0.00	0.00	85	55	0.00
Other Financing Activities, net	90	-2.74	-3.35	-6.85	0.04	0.00	-	-	-3.59	0.00
Effect of Exchange Rate Changes	-0.01	1.30	-1.48	-0.22	0.58	0.74	-	-	-	-
Cash Interest Paid	10	2.01	0.35	0.22	0.01	0.00	-	-	-	-
Cash Income Taxes Paid	0.64	1.25	0.12	0.00	0.01	0.00	-	-	-	-

This table details how cash moves in and out of Verona Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	1.66	64	-69	150	-17	14	-13	-21	64	-3.87	120
Net Cash From Operating Activities	-12	-29	-63	-17	-14	-10	-13	-21	-5.78	-7.74	-18
Net Cash From Continuing Operating Activities	-12	-29	-63	-17	-14	-10	-13	-21	-5.78	-7.74	-18
Net Income / (Loss) Continuing Operations	-16	-34	-43	-71	-26	-14	-15	-8.81	-17	-10	-16
Consolidated Net Income / (Loss)	-16	-34	-43	-71	-26	-14	-15	-8.81	-17	-10	-16
Depreciation Expense	0.30	0.26	0.27	0.27	0.26	0.21	0.16	0.16	0.16	0.15	0.16
Amortization Expense	0.65	0.53	0.49	0.23	0.17	0.04	0.05	0.05	0.09	0.03	0.05
Non-Cash Adjustments To Reconcile Net Income	39	20	-9.63	41	4.48	3.36	6.09	4.33	3.36	2.03	6.67
Changes in Operating Assets and Liabilities, net	-35	-16	-11	13	7.27	0.12	-4.33	-17	7.36	0.50	-9.32
Net Cash From Investing Activities	-0.54	-0.54	-	-0.03	-0.02	-	-	-	0.00	-	-
Net Cash From Continuing Investing Activities	-0.54	-0.54	-	-0.03	-0.02	-	-	-	0.00	-	-
Purchase of Property, Plant & Equipment	-0.54	-0.54	-	-0.03	-0.02	-	-	-	0.00	-	-
Net Cash From Financing Activities	13	94	-7.09	167	-3.12	24	0.05	0.12	69	2.61	140
Net Cash From Continuing Financing Activities	13	94	-7.09	167	-3.12	24	0.05	0.12	69	2.61	140
Repayment of Debt	0.00	-	-4.61	-54	-0.36	29	-	-	0.00	-	-
Repurchase of Preferred Equity	-110	-	-	-	-	-	-	-	-	-	-
Issuance of Debt	123	-	-	123	0.00	-	-	-	10.00	10	-
Other Financing Activities, net	0.88	-3.34	-2.48	99	-2.76	-4.69	0.05	0.08	1.83	-1.34	-0.53
Effect of Exchange Rate Changes	0.30	-1.07	1.18	0.02	-0.14	0.80	-0.68	0.50	0.69	1.25	-1.33
Cash Interest Paid	10	3.88	4.43	1.09	0.93	0.78	0.54	0.44	0.24	0.16	0.08
Cash Income Taxes Paid	0.00	0.39	0.25	-	-	0.03	-	-	-	0.03	0.09

This table presents Verona Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Total Assets	474	308	259	187	204	56	95	121	57
Total Current Assets	454	290	243	0.00	203	54	91	118	54
Cash & Equivalents	400	272	228	-	188	30	25	42	49
Accounts Receivable	31	0.00	-	-	-	-	-	-	-
Inventories, net	6.25	0.00	-	-	-	-	-	-	-
Prepaid Expenses	7.57	3.62	2.50	-	4.54	1.66	3.14	2.45	3.65
Current Deferred & Refundable Income Taxes	5.76	11	9.28	-	8.26	9.81	5.73	6.76	1.32
Other Current Assets	2.74	3.37	3.39	-	1.72	2.02	-	-	-
Plant, Property, & Equipment, net	1.11	0.02	0.07	0.00	0.11	0.06	0.03	0.02	0.02
Total Noncurrent Assets	20	18	16	0.55	1.60	1.87	3.90	3.26	2.86
Goodwill	0.55	0.55	0.55	0.55	0.55	0.59	0.56	0.60	0.54
Other Noncurrent Operating Assets	19	18	16	-	1.05	1.29	0.00	-	-
Total Liabilities & Shareholders' Equity	474	308	259	0.00	204	56	95	121	57
Total Liabilities	270	59	29	0.00	19	13	14	13	14
Total Current Liabilities	43	8.69	19	0.00	14	13	13	12	13
Accounts Payable	11	3.49	2.91	-	0.18	1.93	9.85	9.66	3.48
Accrued Expenses	17	3.59	14	-	11	8.97	-	-	-
Current Deferred & Payable Income Tax Liabilities	8.89	0.00	0.28	-	0.00	-	-	0.23	0.16
Other Current Liabilities	5.77	1.62	2.08	-	3.16	1.94	0.00	-	-
Total Noncurrent Liabilities	227	50	9.97	0.00	5.15	0.65	1.40	1.39	0.99
Long-Term Debt	120	48	9.77	-	4.64	0.00	-	-	-
Other Noncurrent Operating Liabilities	107	1.78	0.21	-	0.51	0.65	1.27	1.18	0.99
Commitments & Contingencies	0.00	0.00	0.00	-	0.00	0.00	-	-	-
Total Equity & Noncontrolling Interests	205	249	230	0.00	185	43	81	108	43
Total Preferred & Common Equity	205	249	230	0.00	185	43	81	108	43
Total Common Equity	205	249	230	0.00	185	43	81	108	43
Common Stock	773	644	570	-	398	187	158	168	75
Retained Earnings	-562	-388	-333	-	-207	-142	-87	-67	-35
Treasury Stock	-1.66	-1.52	-1.55	-	-1.70	0.00	-	-	-
Accumulated Other Comprehensive Income / (Loss)	-4.60	-4.60	-4.60	-	-4.60	-2.28	-	-	-

This table presents Verona Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	526	382	434	290	292	304	323	275
Total Current Assets	501	364	416	272	277	288	0.00	0.00
Cash & Equivalents	401	336	405	255	257	271	-	-
Accounts Receivable	62	6.90	-	-	-	-	-	-
Inventories, net	7.24	4.32	-	-	-	-	-	-
Prepaid Expenses	11	7.96	5.43	3.62	3.33	0.89	-	-
Current Deferred & Refundable Income Taxes	5.94	5.59	3.68	11	9.51	10	-	-
Other Current Assets	13	3.44	2.58	1.88	6.32	6.06	-	-
Plant, Property, & Equipment, net	1.05	0.04	0.04	0.02	0.01	0.01	0.00	0.00
Total Noncurrent Assets	24	18	18	18	16	16	0.55	0.54
Goodwill	0.55	0.55	0.55	0.55	0.55	0.55	0.55	0.54
Other Noncurrent Operating Assets	23	17	17	18	15	16	-	-
Total Liabilities & Shareholders' Equity	526	382	434	290	292	304	0.00	0.00
Total Liabilities	299	251	266	65	29	31	0.00	0.00
Total Current Liabilities	57	28	48	15	9.01	11	0.00	0.00
Accounts Payable	9.08	6.83	4.15	4.65	0.82	2.49	-	-
Accrued Expenses	32	18	20	8.27	7.40	7.47	-	-
Current Deferred & Payable Income Tax Liabilities	8.89	1.01	1.01	-	0.00	0.00	-	-
Other Current Liabilities	6.24	1.97	24	1.85	0.79	0.99	-	-
Total Noncurrent Liabilities	243	223	218	50	20	20	0.00	0.00
Long-Term Debt	242	120	120	49	20	20	-	-
Other Noncurrent Operating Liabilities	1.06	103	98	1.60	0.02	0.03	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Total Equity & Noncontrolling Interests	227	130	168	225	264	273	0.00	0.00
Total Preferred & Common Equity	227	130	168	225	264	273	0.00	0.00
Total Common Equity	227	130	168	225	264	273	0.00	0.00
Common Stock	811	664	659	645	643	638	-	-
Retained Earnings	-579	-528	-485	-414	-374	-359	-	-
Treasury Stock	-1.40	-0.83	-1.20	-1.28	-0.75	-0.98	-	-
Accumulated Other Comprehensive Income / (Loss)	-4.60	-4.60	-4.60	-4.60	-4.60	-4.60	-	-

This table displays calculated financial ratios and metrics derived from Verona Pharma's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-100.00%	-98.86%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-133.46%	7.83%	-27.06%	15.60%	-57.40%	-26.07%	18.87%	-366.28%	34.71%	0.00%
EBIT Growth	-134.05%	7.63%	-26.55%	15.10%	-57.01%	-27.15%	18.89%	-364.08%	34.52%	0.00%
NOPAT Growth	-128.84%	10.80%	-3.32%	1.30%	-41.74%	-60.73%	18.89%	-364.08%	34.52%	0.00%
Net Income Growth	-218.96%	20.86%	-23.63%	14.70%	-60.61%	-59.98%	8.44%	-347.13%	43.94%	0.00%
EPS Growth	-200.00%	30.77%	-8.33%	52.00%	35.90%	97.94%	19.23%	-15,500.00%	99.60%	0.00%
Operating Cash Flow Growth	-143.33%	16.10%	-80.01%	26.23%	-5.15%	-285.79%	-17.47%	505.64%	-173.58%	0.00%
Free Cash Flow Firm Growth	87.66%	6.34%	-28.84%	2.33%	-39.07%	-60.13%	11.38%	-181.54%	0.00%	0.00%
Invested Capital Growth	-389.19%	108.63%	2,176.51%	-63.74%	-22.25%	25.71%	27.61%	-62.54%	0.00%	0.00%
Revenue Q/Q Growth	651.76%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-1.25%	-9.54%	14.96%	2.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	-1.60%	-9.52%	14.84%	2.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.49%	-6.37%	15.05%	-1.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	-12.81%	-7.26%	15.72%	2.75%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	-8.00%	-28.57%	18.75%	-50.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-17.76%	-5.60%	13.80%	4.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-363.55%	13.17%	-14.87%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	12.49%	-0.72%	2,180.70%	-91.58%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	0.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-351.74%	0.00%	-15,089.30%	-135.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-365.73%	0.00%	-16,539.30%	-183.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-357.61%	0.00%	-15,269.21%	-138.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-410.18%	0.00%	-15,000.22%	-138.92%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	106.31%	100.88%	100.37%	99.97%	100.22%	100.18%	82.46%	81.33%	84.03%	83.24%
Interest Burden Percent	107.89%	83.43%	97.88%	100.59%	99.87%	97.67%	94.30%	84.70%	85.09%	100.31%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-818.79%	-5,011.63%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-804.38%	-5,006.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	759.17%	4,951.51%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-76.42%	-22.67%	-59.62%	-60.12%	-57.25%	-65.67%	-26.87%	-36.81%	-14.56%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	-317.44%	-1,001.96%	-4,918.08%	-3,001.39%	-2,136.60%	-1,688.45%	-1,181.75%	-576.99%	0.00%
Operating Return on Assets (OROA)	-38.65%	0.00%	-31.36%	-28.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-44.33%	0.00%	-30.80%	-28.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-76.42%	-22.67%	-59.62%	-60.12%	-57.25%	-65.67%	-26.87%	-36.81%	-14.56%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-84.78%	-21.81%	-29.81%	0.00%	-35.24%	-94.90%	-31.38%	-25.66%	-14.56%	0.00%
Net Operating Profit after Tax (NOPAT)	-108	-47	-53	-51	-52	-37	-23	-28	-6.06	-9.26
NOPAT Margin	-256.01%	0.00%	-11,577.51%	-128.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-25.93%	-3.20%	-14.41%	-4.65%	-11.73%	-6.46%	-2.72%	0.61%	-0.66%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-33.31%	-15.89%	-22.07%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	360.30%	0.00%	5,878.82%	84.77%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	105.43%	0.00%	10,760.48%	198.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	465.73%	0.00%	16,639.30%	283.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-151	-65	-70	-55	-65	-41	-33	-40	-8.66	-13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-149	-64	-69	-54	-64	-41	-32	-40	-8.59	-13
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	18.58	6.38	8.57	0.00	0.50	1.77	1.57	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	18.63	6.39	8.59	0.00	0.50	1.80	1.65	0.00	0.00	0.00
Price to Revenue (P/Rev)	89.88	0.00	4,314.45	10.08	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	52.76	141.69	739.94	0.00	18.05	30.84	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	83.28	0.00	3,838.34	10.08	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	2.06	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.59	0.19	0.04	0.00	0.03	0.00	0.04	0.00	0.00	0.00
Long-Term Debt to Equity	0.59	0.19	0.04	0.00	0.03	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.11	-0.92	-0.94	-0.99	-0.98	-0.97	-0.99	-0.97	-0.92	0.00
Leverage Ratio	1.72	1.18	1.94	2.11	1.14	1.23	1.15	1.18	1.34	0.00
Compound Leverage Factor	1.86	0.99	1.89	2.13	1.14	1.20	1.08	1.00	1.14	0.00
Debt to Total Capital	37.04%	16.25%	4.07%	0.00%	2.45%	0.00%	3.78%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.78%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	37.04%	16.25%	4.07%	0.00%	2.45%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	62.96%	83.75%	95.93%	0.00%	97.55%	100.00%	96.22%	100.00%	100.00%	0.00%
Debt to EBITDA	-0.81	-0.76	-0.14	0.00	-0.07	0.00	-0.10	0.00	0.00	0.00
Net Debt to EBITDA	1.88	3.51	3.16	0.00	2.85	0.00	2.44	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.81	-0.76	-0.14	0.00	-0.07	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-1.11	-1.02	-0.18	0.00	-0.09	0.00	-0.14	0.00	0.00	0.00
Net Debt to NOPAT	2.58	4.72	4.11	0.00	3.53	0.00	3.47	0.00	0.00	0.00
Long-Term Debt to NOPAT	-1.11	-1.02	-0.18	0.00	-0.09	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.87	14.84	39.23	0.00	1.49	-1.71	3.84	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.63	33.33	12.77	0.00	14.26	4.23	7.01	10.13	4.03	0.00
Quick Ratio	10.10	31.27	11.97	0.00	13.24	3.18	6.33	9.34	3.66	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-7.50	-61	-65	-50	-52	-37	-23	-26	-9.28	0.00
Operating Cash Flow to CapEx	-21,069.48%	0.00%	-206,420.69%	-277,116.67%	-54,970.73%	-80,883.02%	6,757.83%	229,955.74%	-42,969.36%	635,483.57%
Free Cash Flow to Firm to Interest Expense	-0.28	-29.55	-48.57	-148.12	-1,473.25	0.00	-13.72	-7.85	-9.47	0.00
Operating Cash Flow to Interest Expense	-4.49	-24.42	-44.81	-97.81	-1,287.89	0.00	13.67	8.40	-7.04	87.07
Operating Cash Flow Less CapEx to Interest Expense	-4.51	-24.42	-44.83	-97.84	-1,290.23	0.00	13.47	8.39	-7.05	87.06
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.11	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	74.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-75	26	12	0.55	1.50	1.93	1.54	1.20	3.22	0.00
Invested Capital Turnover	-1.73	0.00	0.07	39.06	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-101	13	12	-0.96	-0.43	0.40	0.33	-2.01	3.22	0.00
Enterprise Value (EV)	3,521	1,366	1,758	403	-91	35	47	0.00	0.00	0.00
Market Capitalization	3,800	1,589	1,976	403	92	76	127	0.00	0.00	0.00
Book Value per Share	$0.31	$0.39	$0.38	$0.00	$1.76	$0.41	$0.77	$1.03	$0.00	$0.00
Tangible Book Value per Share	$0.31	$0.39	$0.38	$0.00	$1.75	$0.40	$0.73	$1.00	$0.00	$0.00
Total Capital	325	298	240	0.00	189	43	84	108	43	0.00
Total Debt	120	48	9.77	0.00	4.64	0.00	3.17	0.00	0.00	0.00
Total Long-Term Debt	120	48	9.77	0.00	4.64	0.00	0.00	0.00	0.00	0.00
Net Debt	-279	-223	-218	0.00	-183	-41	-79	-108	-49	0.00
Capital Expenditures (CapEx)	0.58	0.00	0.03	0.01	0.08	0.05	0.34	0.01	0.02	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	11	9.24	-3.86	0.00	0.32	0.65	-0.98	-2.40	-8.45	0.00
Debt-free Net Working Capital (DFNWC)	411	281	224	0.00	188	41	81	106	41	0.00
Net Working Capital (NWC)	411	281	224	0.00	188	41	78	106	41	0.00
Net Nonoperating Expense (NNE)	65	7.07	16	4.25	13	3.88	2.53	-0.45	0.13	1.79
Net Nonoperating Obligations (NNO)	-279	-223	-218	0.55	-183	-41	-79	-107	-39	0.00
Total Depreciation and Amortization (D&A)	2.48	0.90	0.82	0.87	0.64	0.51	0.12	0.17	0.08	0.08
Debt-free, Cash-free Net Working Capital to Revenue	26.33%	0.00%	-842.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	971.86%	0.00%	48,901.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	971.86%	0.00%	48,901.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.27)	($0.09)	($0.13)	($0.12)	($0.25)	($30.30)	($0.19)	($23.40)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	652.31M	634.14M	631.90M	482.94M	463.48M	105.33M	105.33M	105.02M	0.00	0.00
Adjusted Diluted Earnings per Share	($0.27)	($0.09)	($0.13)	($0.12)	($0.25)	($30.30)	($0.19)	($23.40)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	652.31M	634.14M	631.90M	482.94M	463.48M	105.33M	105.33M	105.02M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.12)	($0.25)	($30.30)	($0.19)	($23.40)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	679.83M	646.52M	631.90M	482.94M	463.48M	105.33M	105.33M	105.02M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-108	-47	-53	-51	-52	-37	-23	-28	-6.06	-9.26
Normalized NOPAT Margin	-256.01%	0.00%	-11,577.51%	-128.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-385.84%	0.00%	-14,944.98%	-138.97%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.56	-31.40	-52.35	-162.53	-1,859.60	0.00	-19.31	-12.07	-8.84	-122.96
NOPAT to Interest Expense	-3.98	-22.99	-39.69	-150.94	-1,485.54	0.00	-13.52	-8.45	-6.19	-86.07
EBIT Less CapEx to Interest Expense	-5.58	-31.40	-52.37	-162.57	-1,861.94	0.00	-19.52	-12.08	-8.86	-122.97
NOPAT Less CapEx to Interest Expense	-4.00	-22.99	-39.71	-150.97	-1,487.88	0.00	-13.72	-8.45	-6.21	-86.09
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-13.88%	0.00%	-19.57%	0.00%	0.00%	0.00%	-12.67%	0.00%

This table displays calculated financial ratios and metrics derived from Verona Pharma's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%
EBITDA Growth	66.29%	-11.05%	-111.27%	-512.09%	-41.12%	-50.16%	-8.69%	37.56%	23.55%	52.35%	-239.73%
EBIT Growth	63.30%	-14.12%	-113.14%	-505.35%	-41.56%	-49.95%	-8.53%	37.17%	23.22%	52.03%	-244.28%
NOPAT Growth	62.07%	3.95%	-149.32%	-586.63%	-22.52%	-26.88%	-7.82%	51.41%	11.43%	47.13%	-263.36%
Net Income Growth	36.73%	-139.36%	-192.52%	-704.30%	-54.06%	-35.22%	6.14%	50.43%	32.59%	55.07%	-241.59%
EPS Growth	50.00%	-66.67%	-250.00%	-1,000.00%	-33.33%	-200.00%	33.33%	75.00%	40.00%	75.00%	-250.00%
Operating Cash Flow Growth	15.06%	-177.22%	-392.30%	19.75%	-135.39%	-34.43%	29.67%	-9.19%	60.16%	55.33%	-179.28%
Free Cash Flow Firm Growth	-49.39%	427.47%	325.05%	466.09%	-110.90%	-19.86%	-693.23%	-345.49%	-106.84%	-18.07%	-71,733.34%
Invested Capital Growth	258.79%	-389.19%	-428.09%	-624.85%	3,322.39%	108.63%	4,692.65%	410.76%	135.64%	2,176.51%	-91.60%
Revenue Q/Q Growth	108.04%	551.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%
EBITDA Q/Q Growth	51.76%	49.90%	45.08%	-154.00%	-58.91%	4.69%	-59.11%	41.44%	-69.10%	31.01%	8.60%
EBIT Q/Q Growth	48.80%	48.82%	44.37%	-151.76%	-59.20%	4.41%	-58.01%	41.13%	-68.63%	30.81%	8.53%
NOPAT Q/Q Growth	43.74%	54.90%	40.57%	-151.57%	-42.44%	-17.06%	-63.68%	55.11%	-47.51%	0.52%	26.23%
Net Income Q/Q Growth	51.76%	21.26%	39.35%	-174.62%	-82.52%	3.78%	-66.77%	47.40%	-60.20%	33.21%	11.93%
EPS Q/Q Growth	60.00%	28.57%	36.36%	-175.00%	-33.33%	-50.00%	-100.00%	66.67%	-200.00%	66.67%	25.00%
Operating Cash Flow Q/Q Growth	59.91%	53.98%	-266.36%	-25.66%	-30.84%	18.27%	40.28%	-268.57%	25.28%	57.24%	7.29%
Free Cash Flow Firm Q/Q Growth	-163.13%	5.72%	-8.60%	344.89%	-38.38%	27.34%	-48.69%	-41.07%	21.36%	-380.85%	16.49%
Invested Capital Q/Q Growth	189.40%	12.49%	26.66%	-725.34%	-27.94%	-0.72%	17.32%	3,977.61%	-95.61%	2,180.70%	-87.50%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%
EBITDA Margin	-11.67%	-50.33%	-654.73%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,415.28%	0.00%
Operating Margin	-13.53%	-50.03%	-723.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,285.81%	0.00%
EBIT Margin	-12.91%	-52.47%	-668.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,454.15%	0.00%
Profit (Net Income) Margin	-21.40%	-92.28%	-763.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,281.88%	0.00%
Tax Burden Percent	98.56%	132.36%	100.59%	101.45%	103.01%	99.63%	100.30%	103.65%	101.04%	100.27%	100.41%
Interest Burden Percent	168.15%	132.88%	113.66%	103.36%	93.32%	84.16%	83.05%	76.14%	87.42%	92.73%	95.92%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-26.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-162.67%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-21.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-162.74%	0.00%
Return on Net Nonoperating Assets (RNNOA)	17.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	153.60%	0.00%
Return on Equity (ROE)	-9.00%	-76.42%	-78.03%	-56.85%	-56.38%	-22.67%	0.00%	0.00%	-95.97%	-9.07%	-96.92%
Cash Return on Invested Capital (CROIC)	-338.17%	0.00%	0.00%	0.00%	-717.87%	-317.44%	-525.96%	-462.94%	-9,741.80%	-1,001.96%	-1,609.26%
Operating Return on Assets (OROA)	-3.75%	-5.67%	-11.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5.04%	0.00%
Return on Assets (ROA)	-6.22%	-9.97%	-12.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4.69%	0.00%
Return on Common Equity (ROCE)	-9.00%	-76.42%	-78.03%	-56.85%	-56.38%	-22.67%	0.00%	0.00%	-95.97%	-9.07%	-96.92%
Return on Equity Simple (ROE_SIMPLE)	-72.35%	0.00%	-117.80%	-74.55%	-28.19%	0.00%	-19.23%	-18.91%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.22	-13	-28	-48	-19	-13	-11	-6.98	-16	-11	-11
NOPAT Margin	-9.47%	-35.02%	-506.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,300.07%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.97%	-8.35%	-6.39%	-8.56%	-6.57%	-0.35%	-2.76%	-1.02%	-1.89%	0.08%	-6.28%
Return On Investment Capital (ROIC_SIMPLE)	-1.54%	-3.95%	-	-	-	-4.49%	-	-	-	-4.39%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	95.10%	128.56%	635.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,892.79%	0.00%
R&D to Revenue	18.43%	21.47%	187.62%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,493.01%	0.00%
Operating Expenses to Revenue	113.53%	150.03%	823.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3,385.81%	0.00%
Earnings before Interest and Taxes (EBIT)	-9.85	-19	-38	-68	-27	-17	-18	-11	-19	-11	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-8.90	-18	-37	-67	-26	-17	-17	-11	-19	-11	-16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	23.81	18.58	17.91	6.97	5.78	6.38	4.92	6.15	0.00	8.57	0.00
Price to Tangible Book Value (P/TBV)	23.87	18.63	17.99	6.99	5.79	6.39	4.93	6.16	0.00	8.59	0.00
Price to Revenue (P/Rev)	45.52	89.88	415.56	0.00	0.00	0.00	2,828.81	3,667.58	3,463.06	4,314.45	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	78.23	0.00	0.00	0.00	58.65	52.76	40.59	64.30	2,910.24	141.69	1,145.13
Enterprise Value to Revenue (EV/Rev)	44.17	83.28	377.15	0.00	0.00	0.00	2,310.34	3,119.83	3,463.06	3,838.34	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	745.66	18.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.07	0.59	0.92	0.71	0.22	0.19	0.08	0.07	0.00	0.04	0.00
Long-Term Debt to Equity	1.07	0.59	0.92	0.71	0.22	0.19	0.08	0.07	0.00	0.04	0.00
Financial Leverage	-0.81	-1.11	-1.15	-1.21	-0.91	-0.92	-0.90	-0.93	-1.01	-0.94	-0.96
Leverage Ratio	1.81	1.72	1.71	1.67	2.72	1.18	2.15	1.19	3.90	1.94	2.83
Compound Leverage Factor	3.04	2.29	1.95	1.73	2.54	1.00	1.79	0.91	3.41	1.79	2.72
Debt to Total Capital	51.62%	37.04%	47.91%	41.56%	17.75%	16.25%	7.02%	6.78%	0.00%	4.07%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	51.62%	37.04%	47.91%	41.56%	17.75%	16.25%	7.02%	6.78%	0.00%	4.07%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	48.38%	62.96%	52.09%	58.44%	82.25%	83.75%	92.98%	93.22%	0.00%	95.93%	0.00%
Debt to EBITDA	-1.84	-0.81	-0.82	-0.94	-0.68	-0.76	-0.34	-0.35	0.00	-0.14	0.00
Net Debt to EBITDA	1.22	1.88	1.47	2.23	2.89	3.51	4.08	4.42	0.00	3.16	0.00
Long-Term Debt to EBITDA	-1.84	-0.81	-0.82	-0.94	-0.68	-0.76	-0.34	-0.35	0.00	-0.14	0.00
Debt to NOPAT	-2.51	-1.11	-1.10	-1.30	-0.96	-1.02	-0.45	-0.46	0.00	-0.18	0.00
Net Debt to NOPAT	1.66	2.58	1.99	3.11	4.06	4.72	5.34	5.75	0.00	4.11	0.00
Long-Term Debt to NOPAT	-2.51	-1.11	-1.10	-1.30	-0.96	-1.02	-0.45	-0.46	0.00	-0.18	0.00
Altman Z-Score	10.45	7.79	4.39	1.58	10.77	15.35	25.97	32.00	0.00	39.98	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.86	10.63	13.03	8.61	18.40	33.33	30.68	26.29	0.00	12.77	0.00
Quick Ratio	8.20	10.10	12.27	8.37	17.25	31.27	28.56	24.73	0.00	11.97	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-55	88	83	91	-37	-27	-37	-25	-18	-22	-4.66
Operating Cash Flow to CapEx	-2,160.93%	-5,389.91%	0.00%	-58,972.41%	-85,062.50%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-5.23	8.52	8.41	16.81	-23.42	-43.09	-92.13	-33.58	-60.11	-21.43	-40.15
Operating Cash Flow to Interest Expense	-1.09	-2.80	-6.34	-3.16	-8.58	-16.70	-31.74	-28.80	-19.73	-7.40	-155.99
Operating Cash Flow Less CapEx to Interest Expense	-1.14	-2.85	-6.34	-3.17	-8.59	-16.70	-31.74	-28.80	-19.73	-7.40	-155.99
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.29	0.11	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	221.56	74.90	224.96	0.00	0.00	0.00	0.00	8.98	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.06	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6,254.05	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-6,254.05	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	67	-75	-86	-117	19	26	26	22	0.55	12	0.54
Invested Capital Turnover	2.77	-1.73	-0.19	0.00	0.00	0.00	0.03	0.03	-0.93	0.07	0.00
Increase / (Decrease) in Invested Capital	48	-101	-112	-139	18	13	26	18	2.07	12	-5.93
Enterprise Value (EV)	5,236	3,521	2,121	888	1,094	1,366	1,058	1,429	1,586	1,758	623
Market Capitalization	5,395	3,800	2,337	1,172	1,300	1,589	1,296	1,680	1,586	1,976	623
Book Value per Share	$0.33	$0.31	$0.20	$0.26	$0.35	$0.39	$0.41	$0.43	$0.00	$0.38	$0.00
Tangible Book Value per Share	$0.33	$0.31	$0.20	$0.26	$0.35	$0.39	$0.41	$0.43	$0.00	$0.38	$0.00
Total Capital	468	325	251	288	274	298	283	293	0.00	240	0.00
Total Debt	242	120	120	120	49	48	20	20	0.00	9.77	0.00
Total Long-Term Debt	242	120	120	120	49	48	20	20	0.00	9.77	0.00
Net Debt	-160	-279	-216	-285	-206	-223	-237	-251	0.00	-218	0.00
Capital Expenditures (CapEx)	0.54	0.54	0.00	0.03	0.02	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	43	11	0.26	-37	2.18	9.24	10	6.16	0.00	-3.86	0.00
Debt-free Net Working Capital (DFNWC)	444	411	336	368	257	281	268	277	0.00	224	0.00
Net Working Capital (NWC)	444	411	336	368	257	281	268	277	0.00	224	0.00
Net Nonoperating Expense (NNE)	9.10	21	14	23	6.76	0.77	3.27	1.83	1.20	-0.08	5.06
Net Nonoperating Obligations (NNO)	-160	-279	-216	-285	-206	-223	-237	-251	0.55	-218	0.54
Total Depreciation and Amortization (D&A)	0.95	0.79	0.76	0.50	0.44	0.24	0.20	0.21	0.25	0.18	0.21
Debt-free, Cash-free Net Working Capital to Revenue	36.33%	26.33%	4.68%	0.00%	0.00%	0.00%	2,215.94%	1,343.89%	0.00%	-842.79%	0.00%
Debt-free Net Working Capital to Revenue	374.98%	971.86%	5,979.78%	0.00%	0.00%	0.00%	58,409.39%	60,454.59%	0.00%	48,901.09%	0.00%
Net Working Capital to Revenue	374.98%	971.86%	5,979.78%	0.00%	0.00%	0.00%	58,409.39%	60,454.59%	0.00%	48,901.09%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.02)	($0.05)	($0.07)	($0.11)	($0.04)	($0.03)	($0.02)	($0.01)	($0.03)	($0.01)	($0.03)
Adjusted Weighted Average Basic Shares Outstanding	679.41M	652.31M	651.94M	648.22M	645.70M	634.14M	638.24M	634.47M	621.45M	529.07M	544.13M
Adjusted Diluted Earnings per Share	($0.02)	($0.05)	($0.07)	($0.11)	($0.04)	($0.03)	($0.02)	($0.01)	($0.03)	($0.01)	($0.03)
Adjusted Weighted Average Diluted Shares Outstanding	679.41M	652.31M	651.94M	648.22M	645.70M	634.14M	638.24M	634.47M	621.45M	529.07M	544.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	681.06M	679.83M	654.65M	649.88M	648.65M	646.52M	639.52M	635.88M	635.67M	631.90M	604.98M
Normalized Net Operating Profit after Tax (NOPAT)	-7.22	-13	-28	-48	-19	-13	-11	-6.98	-16	-11	-11
Normalized NOPAT Margin	-9.47%	-35.02%	-506.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,300.07%	0.00%
Pre Tax Income Margin	-21.71%	-69.72%	-759.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,275.76%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.93	-1.86	-3.80	-12.49	-16.92	-27.05	-43.97	-15.08	-64.69	-10.76	-140.05
NOPAT to Interest Expense	-0.68	-1.24	-2.88	-8.85	-12.00	-21.45	-28.47	-9.43	-53.04	-10.08	-91.29
EBIT Less CapEx to Interest Expense	-0.98	-1.92	-3.80	-12.49	-16.93	-27.05	-43.97	-15.08	-64.69	-10.76	-140.05
NOPAT Less CapEx to Interest Expense	-0.73	-1.30	-2.88	-8.86	-12.01	-21.45	-28.47	-9.43	-53.04	-10.08	-91.29
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-13.88%	-11.76%

Frequently Asked Questions About Verona Pharma's Financials

When does Verona Pharma's financial year end?

According to the most recent income statement we have on file, Verona Pharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Verona Pharma's net income changed over the last 9 years?

Verona Pharma's net income appears to be on an upward trend, with a most recent value of -$173.42 million in 2024, rising from -$11.05 million in 2015. The previous period was -$54.37 million in 2023. See where experts think Verona Pharma is headed by visiting Verona Pharma's forecast page.

What is Verona Pharma's operating income?

Verona Pharma's total operating income in 2024 was -$154.63 million, based on the following breakdown:

Total Gross Profit: $42.28 million
Total Operating Expenses: $196.91 million

How has Verona Pharma revenue changed over the last 9 years?

Over the last 9 years, Verona Pharma's total revenue changed from $0.00 in 2015 to $42.28 million in 2024, a change of 4,227,900,000.0%.

How much debt does Verona Pharma have?

Verona Pharma's total liabilities were at $269.68 million at the end of 2024, a 358.3% increase from 2023, and a 1,772.3% increase since 2016.

How much cash does Verona Pharma have?

In the past 8 years, Verona Pharma's cash and equivalents has ranged from $0.00 in 2021 to $399.76 million in 2024, and is currently $399.76 million as of their latest financial filing in 2024.

How has Verona Pharma's book value per share changed over the last 9 years?

Over the last 9 years, Verona Pharma's book value per share changed from 0.00 in 2015 to 0.31 in 2024, a change of 31.3%.

Related Companies

This page (NASDAQ:VRNA) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verona Pharma (VRNA) Financials

Frequently Asked Questions About Verona Pharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verona Pharma (VRNA) Financials

Annual Income Statements for Verona Pharma

Quarterly Income Statements for Verona Pharma

Annual Cash Flow Statements for Verona Pharma

Quarterly Cash Flow Statements for Verona Pharma

Annual Balance Sheets for Verona Pharma

Quarterly Balance Sheets for Verona Pharma

Annual Metrics And Ratios for Verona Pharma

Quarterly Metrics And Ratios for Verona Pharma

Frequently Asked Questions About Verona Pharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools